Anti-acne agents (A61P17/10)

A   Human necessities(304962)
A61P17        Drugs for dermatological disorders(1531)
A61P17/10                     Anti-acne agents(94)
Combination for acne treatment and method of its application // 2614392
FIELD: pharmacy.SUBSTANCE: combination for acne treatment, comprising an aqueous Gynura Procumbens leaf extract, and means containing non-activated platelets and white blood cells in their own blood plasma. A method of acne treatment by application of the above combination.EFFECT: combination and treatment method are characterized by high efficiency in acne treatment.2 cl, 2 dwg

Ways of acne treatment // 2613708
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine, namely to dermatology, and can be used to treat acne. To do this, plating of B. bifidum №1 suspension in saline solution ( 106 Cfu/ml) prepared from "Bifidumbacterin" with 100: 1 ratio into a sterile thioglycolic environment is performed, then it is incubated at (371±)°C during 48 h, the sterile gauze is impregnated with the resulting broth culture of bifidobacteria and applied on the affected skin for 30 minutes, the procedure is repeated 2 times a day.EFFECT: invention provides reduction in virulence of pathogens and persistent properties of acne due to the action of exometabolites and intact cells of lactic acid bacteria.3 dwg, 1 tbl, 3 ex
Acne treating method and composition against acne // 2613107
FIELD: cosmetology.SUBSTANCE: invention relates to cosmetology and dermatology and represents composition against acne, containing, at least, one active ingredient, selected from group, including compounds of formula I and formula II based on coumarin and, at least, one pharmaceutically acceptable filler, where amount of said vegetal component ranges from 0.001 to 25% of total weight of composition.EFFECT: invention provides extended range of products applicable for treating acne, high inhibiting activity relative to Propionibacterium acne.13 cl, 1 tbl, 1 ex
Cosmetic composition of fluid formed during hatching fish roe // 2611639
FIELD: cosmetics.SUBSTANCE: invention refers to cosmetic and pharmaceutical industry and represents a method for producing a cosmetic composition of fluid formed during the hatching of fish roe, including at least the following steps: (a) suspending of fish roe in minimal volume of water; (b) induction of synchronized fast hatching said caviar, preferably so, that hatching is terminated for less than 6 hours for more than 80% of embryos; (c) filtration of liquid, formed at hatching, from step (b) to obtain a composition, note here that said fluid filtration stage, formed at hatching includes a liquid filter formed at hatching, using a filter with pore size of at least 5 mcm and collecting of the filtrate; (d) treating the filtrate from stage (c) by means of ion-exchange chromatography, including: (1) loading of the filtrate to ion-exchange column, preferably on DEAE (diethylaminoethylic) column; (2) washing the column by suitable buffer, preferably buffered by irrigating solution with pH 7–9; (3) elution of column leucolectin polypeptides using first elution buffer or solvent, note here that preferably the first elution buffer comprises buffered flushing solution, additionally contains salt in concentration of 50 to 100 mM; (4) elution from column of remaining polypeptides using second elution buffer or solvent, at that, preferably second elution buffer comprises buffered flushing solution, containing salt in concentration of 500 mM to 2 M; (5) collecting eluate from step (4); (e) replacement of water in the eluate from step (5) on a cosmetically acceptable buffer; (f) filtering the solution obtained at step (e), using a filter with pore size of 0.15–0.30 mcm and collecting the filtrate; and (g) preparation of said cosmetic composition from the filtrate obtained at step (f).EFFECT: invention provides effective skin moistening and pilling of the stratum corneum.25 cl, 7 dwg, 1 tbl, 6 ex
Composition for face washing // 2610172
FIELD: cosmetology.SUBSTANCE: invention relates to cosmetology and dermatology and represents a composition for face washing for topical application containing in a cosmetically acceptable carrier from 1 to 10 % of an active substances of fine zinc sulphate with respect to the total weight of the composition, from 0.15 to 0.3 % of zinc gluconate expressed in the form of the weight ratio with respect to the total weight of the composition, and from 0.15 to 0.3 % of dipotassium glycyrrhizate expressed in the form of the weight ratio with respect to the total weight of the composition.EFFECT: invention provides a stable and well-tolerated composition, which effectively cleans the skin in patients suffering acne without any disturbance of the skin barrier and does not cause overcompensation of the sebum production.6 cl, 19 ex
ethod of treating acne // 2600052
FIELD: medicine; cosmetology.SUBSTANCE: invention refers to medicine, namely to cosmetology and dermatology, and can be used for treating acne. Perform complex therapy sessions carried out in sessions every second day. Thus 1st session includes cleansing the skin with antiseptic gel, vaporization, manual cleaning, processing with antiseptic lotion, darsonvalization performance, point and lymphatic drainage massage and the subsequent application of anti-inflammatory mask, and then - a protective cream or serum, cryomassage application. 2nd session after skin cleansing includes application of specified anti-inflammatory mask and subsequent application of mask with dissolving and exfoliating action, implementation of massage, darsonvalization and cryomassage performance and skin treatment at bedtime in the area of acne using therapeutic lotion. 3rd session after skin cleansing includes application of anti-inflammatory mask, antiseptic mask and darsonvalization and cryomassage performance locally on the affected elements. While at the 2nd session, after the application of mask with dissolving and exfoliating action, with its subsequent rinsing and drying of the skin perform therapeutic facial massage. To do this perform nine sequentially executed steps. Thus 1st stage includes stroking of the chin, cheeks, forehead. 2nd stage involves kneading the forehead, cheeks and chin. 3-ND stage includes pincer fulling of chin and cheeks, including along vertical lines, - from the middle of the chin to the nose wings; from the middle from beneath the angle of lower part of the jaw to the middle of the cheek; from the angle of the lower jaw bone - to the lateral surface of the cheeks. 3rd stage if finished using the "Snail" technique, consisting in the implementation of sixteen deep pinches from the lateral surface of the cheek in a downward direction, passing through the edge of the lower jaw, spinning along a spiral line to the middle of the cheek. 4th stage comprises circular grinding with circular and spiral movements. 5th stage includes forehead kneading along vertical lines. 6th stage involves light patting movements, “stacatto" on the forehead, cheeks and chin. 7th stage involves a deep vibration pinches, including ones along vertical lines of the lower part of the face. 7th stage if finished using the "Snail" technique. 8th stage is the same as 4th. 9th stage involves stroking; massage is done with light pressure on temples with both hands.EFFECT: method provides more efficient treatment, deep skin cleansing, elimination of inflammation, elimination of infection, elimination of toxins and impurities, full recovery of skin functions by achieving a stable therapeutic effect, improvement of blood circulation in the subcutaneous capillaries, acceleration of metabolic processes in the skin affected by acne due to the deeper and more intensive effect in conducting therapeutic massage.3 cl, 5 ex

Diketones and hydroxyketones as activators of catenin signalling pathway // 2592694
FIELD: pharmaceutics. SUBSTANCE: present invention relates to compounds or pharmaceutically acceptable salts thereof of general formula I, where R1 is ; R2 is selected from a group consisting of substituted or unsubstituted phenyl and , and ; and R3, R4, R5 and R6 all denote H, as well as to compounds II and III. EFFECT: invention also relates to pharmaceutical compositions based on said compounds, method of activating a Wnt signal transmission, methods of treating diseases associated with signal transduction, and use thereof for treating such diseases as osteoporosis and osteoarthropathy; imperfect osteogenesis, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, head face defects, oncolytic bone disease, traumatic brain injury, relating to differentiation and developing central nervous system, including Parkinson's disease, stroke, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases, such as age-related macular degeneration, diabetic macular oedema or pigment pigmentosa and disease related to differentiation and growth of stem cells, including hair loss, disease related to hematopoiesis, and diseases associated with tissue regeneration. 39 cl, 2 tbl, 5 ex
Device and method for local treatment of papulo-papulopustular shape rosacea // 2583559
FIELD: medicine.SUBSTANCE: invention relates to dermatovenerology and may be used for local treatment of papulo papulopustular shape rosacea. Method involves desintoxication therapy, which includes antihistamine and sedative druges in combination with local pharmacotherapy. Local therapy is conducted by following procedure: on clean face on affected areas are applied 5 % sulphuric ointment 2 times a day in morning and in evening for 3 days, then 10 % sulphuric ointment 2 times a day in morning and in evening for 3 days, then 20 % sulphuric ointment 10 days 2 times a day in morning and evening, then gel Azelik 15 % aqueous 2 times a day on dry clean face in morning and in evening for 3-4 months, then 1 time a day in morning for 3-4 months, throughout course for washing in morning and evening, foam is used for washing Setafil® Dermacontrol™ and wetting agent for face Setafil® Dermacontrol™ SPF30 1 time a day in morning after washing with foam.EFFECT: use of invention improves clinical effectiveness by reducing number of recurrences and complications.1 cl, 1 ex
ethod for outpatient treatment of facial skin of patients with rosacea // 2577297
FIELD: medicine.SUBSTANCE: conventional drug therapy involving detoxification therapy, administration of antihistamines and anxiolytics, metronidazole and coating of the affected skin areas with skin care products is accompanied by the local applications of 15% Azelik gel to the affected areas of clean and dried facial skin, twice a day - in the morning and evening for 3-4 months, further once a day in the morning for 3-4 months; during the treatment and on completion thereof, Joyskin care products are used for a daily care routine: cleansing tonic 2-3 times a day, intensive moisturizing cream 2-3 times daily after cleansing with the tonic, and 30-40 minutes after the application of the medicinal product.EFFECT: method allows providing the more effective facial skin treatment in the patients with rosacea and extending the range of care products.1 ex
Cosmetic or dermatological composition for local application // 2571491
FIELD: medicine.SUBSTANCE: as main natural active ingredient compositions contain rhizome of black cohosh (Rhizoma cimicifugae racemosae) for prevention and treatment of skin diseases, selected from acne, seborrhoea, atopic eczema (neurodermatitis), hirsutism, psoriasis and dry/allergy-predisposed skin in people, as well as additional auxiliary agents and/or additives. Application of dermatological composition for prevention and treatment of skin diseases. Pharmaceutical medication, containing dermatological composition.EFFECT: increased efficiency of prophylaxis and treatment of skin diseases.12 cl, 1 ex

Gel compositions with brimonidine and methods of application // 2571277
FIELD: medicine.SUBSTANCE: group of inventions relates to gel composition for local application, which contains from 0.05 to 0.20 wt % of methylparaben as preservative; one or more additional preservatives; from 0.80 to 1.50 wt % of carbomer; from 9.0 to 13.0 wt % of the total content of polyatomic alcohols, in particular propyleneglycol and glycerol; active ingredient, containing agonist of alpha-adrenergic receptors or its pharmaceutically acceptable salt, in particular brimonidine tartrate, and purified water, in which the total quantity of all ingredients equals 100%, composition pH constitutes from 4.5 to 7.5, and where when methylparaben concentration is higher than 0.15 wt %, carbomer concentration constitutes less than 1.25 wt %, and to method of treatment or prevention of skin disease in patient.EFFECT: creation of improved gel composition for local application, which in fact does not contain methylparaben crystals and possesses microbiological purity.15 cl, 2 ex, 3 tbl

Compositions, containing paulownin and/or paulownia extracts and application thereof // 2571075
FIELD: medicine.SUBSTANCE: method of reducing inflammation on skin, which requires reduction of inflammation, includes application on skin, demonstrating inflammation resulting from impact of sun rays, couperose or acne, of effective for inflammation reduction quantity of paulownin-containing polar extract of Paulownia tomentosa wood.EFFECT: extension of arsenal of medications, reducing inflammation on skin.20 cl, 21 ex, 20 tbl

Tofa analogues, applicable in treatment of dermatological disorders or conditions // 2561729
FIELD: medicine, pharmaceutics.SUBSTANCE: invention describes analogues of 5-(tetradecyloxy)-2-furoic acid (TOFA) of formula , where R1 represents -O-R2, R2 independently represents heterocyclylalkyl or halogenalkyl; or R1 represents -O-R3-C(O)N(R5)R6, each R3 represents alkylene chain and R4 represents optionally substituted alkyl or optionally substituted phenyl, each R5 independently represents hydrogen, alkyl or cycloalkyl and each R6 represents alkyl, cycloalkyl, benzyl or -R3-C(O)OR4; or any R5 and R6 together with nitrogen atom, which they are both bound to, form optionally substituted N-heterocyclyl, or its pharmaceutically acceptable salts.EFFECT: invention relates to pharmaceutical compositions for treatment of dermatological disorders or conditions, characterised by hyperactivity of sebaceous glands, such as acne and greasy skin, and other dermatological disorders and conditions, containing TOFA analogues and pharmaceutically acceptable excipient for dermatological or peroral introduction.24 cl, 3 dwg, 6 tbl, 33 ex

Topical agent for acne // 2560698
FIELD: medicine.SUBSTANCE: invention represents a topical agent for acne containing azelaic acid, silicone glycerohydrogel, propylene glycol, Carbomer, triglycerides, phosphatidylcholine, benzoic acid, emulsion wax, glyceryl stearate, triethanolamine and purified water. The ingredients of the agent are taken in a certain ratio, wt %.EFFECT: higher therapeutic efficacy, avoiding side effects and ensuring physiological properties of the skin.2 tbl

ethod of treating patients with acne vulgaris and connective tissue dysplasia // 2557991
FIELD: medicine.SUBSTANCE: method involves administering Aevit, Unidox as a background therapy of degree I and II, and Isotretinoin and Cynovit gel as a background therapy of degree III and IV. Besides, Magnerot® 3.0 g is taken once a day (1.0 g three times a day) throughout the all background therapy.EFFECT: invention enables providing higher clinical effectiveness in the patients with acne and connective tissue dysplasia.1 tbl, 4 dwg

Stable gel form of azelaic acid // 2557932
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutics. Gel form of azelaic acid is described. Gel form includes micronized azelaic acid and additional substances: benzoic acid, disodium edetate, carbomer Carbopol 980, propylene glycol, sodium hydroxide, glycoceramides purified, isopropylmiristate, polysorbate 20, purified water.EFFECT: invention is provided by obtaining stable medication in form of gel, which does not produce local irritating action in case of long-term on-skin applications.11 cl, 15 dwg, 5 tbl
ethod of treating chronic opisthorchiasis in patients with rosacea // 2556962
FIELD: medicine.SUBSTANCE: method involves administering an anthelminthic agent in the period of stationary process stage; the anthelminthic treatment is preceded by administering chophytol 200 mg 3 times a day before meals for 14 days; the anthelminthic treatment involves administering Osinol food supplement 2 tablets 3 times a day during meals for 14 days; thereafter, chophytol is taken in a dose of 200 mg 3 times a day before meals for 14 days; 7 days later, the repeated course of the anthelminthic treatment with Osinol food supplement 2 tablets 3 times a day during meals is prescribed to be administered for 14 days; the entire therapeutic course involves washing the face with the Setaphyldermocontrol foaming facial cleanser 2 times a day followed by applying an SPF30 product on the face once after the morning wash.EFFECT: reducing the number of complications and the high efficacy of the anthelminthic treatment.1 ex
ethod of treating chronic opisthorchiasis in patients with rosacea // 2555351
FIELD: medicine.SUBSTANCE: praziquantel is administered in a single dose of 20 mc/kg for the first day of treatment in the daytime, and withdrawn; on the following day, the conducted therapy is added with introducing Gelmicide, a biologically active food supplement, in a dose of 2 capsules with meals for 21 days; the course is repeated 10 days later in a dose of 2 capsules 2 times a day with meals for 14 days.EFFECT: reducing the rate of complications and increasing the high dishelminthisation efficacy.1 ex

ethods of modulating activity of mc5 receptor and treatment of conditions related to thereof // 2555343
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of pharmaceutics, namely, deals with compounds of formula , suitable for reduction of regulation of biological activity of melanocortin-5 receptor (MC5R). Such diseases and/or conditions include, but are not limited by, acne, seborrhoea, seborrheic dermatitis, cancer and inflammatory diseases.EFFECT: compounds of claimed invention can be applied for treatment of diseases and/or conditions, in which reducing regulation of MC5R is favourable.3 cl, 109 ex, 7 tbl

Halogenated biphenols as antibacterial agents // 2549543
FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula (I) : or a salt thereof, wherein R1 and R5 are independently selected from H, OH and alkoxy; R2-R4 and R6-R8 are independently selected from H, OH, F, Cl, Br and I; R9 and R10 are C2-C8 alkenyl; under the condition that at least one of R1, R5 and R7 is OH or alkoxy; at least one of R2-R4, R6 and R8 is F, Cl, Br or I; and R2 and R6 are Cl. The invention also relates to an antibacterial composition and treatment methods.EFFECT: improved properties.18 cl, 7 ex, 10 tbl

Pharmaceutical composition for treating acne and method for preparing it // 2548714
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, and represents a pharmaceutical composition in the form of gel, which contains clindamycin phosphate, a combination of gel-forming polymer and hydrophilic dispersion phase, pH control agent, allantoin and lauryliminodipropionate sodium tocopheryl phosphate; the ingredients of the composition are taken in certain ratio, in g per 100 g.EFFECT: invention provides the high level of antibacterial activity and stability.5 cl, 1 tbl

Improved methods and compositions for safe and effective treatment of telangiectasia // 2535008
FIELD: medicine.SUBSTANCE: present group of inventions refers to medicine, namely to dermatology, and concerns treating telangiectasia or related symptoms. To this effect, an involved skin area is coated with a composition containing from approximately 0.4 wt % to approximately 0.6 wt % brimonidine providing its blood serum or plasma concentration, Cmax of approximately 54±28 pg/ml or less and AUC0-24h of approximately 568±277 pg·h/ml or less.EFFECT: method provides the effective treatment of telangiectasia or related symptoms with no side local and systemic effects.20 cl, 6 dwg, 6 tbl, 3 ex
Comedolytic pharmaceutical composition and method for preparing it // 2530644
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to the pharmaceutical industry and represents a composition for treating acne, rosacea and hyperpigmentation, in the form of a gel which contains anchoic acid, a hydrophobic ingredient, a non-aqueous solvent, an emulsifying agent, a gel-forming polymer, a preserving agent, a pH control agent and additionally methylpyrrolidone with anchoic acid having a particle size of less than 100 mcm, while anchoic acid is related to methylpyrrolidone as 1:0.025 to 1:4.EFFECT: invention provides easy penetration of anchoic acid through a horny layer and its resolution into the oil grand ducts and between skin cells, providing high concentration of anchoic acid that promotes better antibacterial, keratolytic and de-pigmentation effects.5 cl, 2 tbl, 1 ex

3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists // 2530017
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed invention relates to a compound of Formula , where Y represents a group of formula -(CR9R10)-; X is selected from the group, consisting of -C(=O)-, -OC(=O)-, -NHC(=O)-, -(CR11R12)- and -S(-O)2-; Z represents a group of formula -(CR13R14)q-; R1 is selected from the group, consisting of C1-C12alkyl, optionally substituted with one substituent, selected from naphthyl, indole and biphenyl; C2-C12alkenyl, substituted with a substituent, selected from thienyl, naphthyl and phenyl, with the said phenyl being optionally substituted with 1-2 substituents; selected from halogen, trifluoroalkyl, C1-C6alkyl, methoxy and hydroxy; C3-C6cycloalkyl; C6-C10aryl, optionally substituted with 1-2 substituents, selected from halogen, phenyl, amino, phenoxy, C1-C6alkyl, methoxy, hydroxyl and carboxy; and C4-C9heteroaryl, selected from indole, quinoline, quinoxaline, benzofuranyl, benzothiophene, benzimidazole, benzotriazole, benzodioxin, benzothiasole, pyrazole, furyl and isoxazole, optionally substituted with a substituent, selected from C1-C6alkyl and phenyl; R2 and R3 each is independently selected from the group, consisting of H and C1-C12alkyl; R4a is selected from the group, consisting of H, C1-C12alkyl, optionally substituted with phenyl; C2-C12alkenyl, C3-C6cycloalkyl, C6aryl, C(=O)R15, C(=O)NR15R16, C(=O)OR15, SO2R15 and -C(=NR15)-NR16R17; R4d represents hydrogen or R4a and R4b, taken together with a nitrogen atom, which they are bound to, form an optionally substituted heterocyclic fragment, selected from piperidine, morpholine, pyrrolidine and azetidine, where the substituent is selected from C1-C12alkyl, hydroxy, halogen, carboxy and oxo; each R5a and R5b represents H, or R6, R7 and R8 each is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6-C10aryl, optionally substituted with halogen, or taken together with a carbon atom, which they are bound to, two or more of R6, R7 and R8 form a fragment, selected from the group, consisting of C2-C12alkenyl; C3-C6cycloalkyl, optionally substituted with C1-C6alkyl; C6aryl, optionally substituted with 2 substituents, selected from halogen; each R9 and R10 represents H or C1-C12alkyl, substituted with naphthyl; each R11 and R12 represents H; R13 and R14 represent H, or each R15, R16 and R17 is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6aryl, substituted with one substituent, selected from C1-C6alkyl; and C5-heteroaryl, additionally containing one nitrogen atom, with the said heteroaryl representing pyridyl; q represents an integer number, selected from the group, consisting of 2, 3 and 4; r represents 1; or its pharmaceutically acceptable salt. The invention also relates to particular compounds of 1,4-diazepan-2-one derivatives.EFFECT: obtaining 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists.21 cl, 7 tbl, 110 ex
ethod for selecting therapeutic approach to acne in females // 2529789
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to dermatology, and can be used for selecting a therapeutic approach to acne in females by examining biological fluids and prescribing preparations depending on the clinical findings. The biological fluids are blood and urine; blood serum hormones and steroid urine profile are tested, and the derived values are compared to the standard norms specific for the absence of acne, while the preparations are prescribed according to the comparison results. Specifically, if observing an increase of blood luteinising hormone up to 16 mIU/ml, testosterone up to 4 ng/ml, an increase of urine androsterone up to 20 mcmole/24 hours, etiocholanolone up to 11 mcmole/24 hours, total 17-ketosteroids up to 35 mcmole/24 hours, van de Calseyde's discriminant up to 3, the combined oral contraceptive Jess with the anti-androgenic effect. If also observing an increase of immunoreactive protein up to 12.90 mcUnit/ml and insulin-line growth factor 1 up to 361.04 ng/ml, the combined oral contraceptive Jess and Metformine or Metformine are prescribed. If observing a decrease of blood oestradiol up to 140 pmole/l or an increase of the concentration of luteinising hormone up to 7 mIU/ml, dihydroepiandrosterone sulphate up to 4 mmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and testosterone up to 4 nmole/l in blood and an increase of urine androsterone up to 17 mcmole/24 hours, etiocholanolone up to 17 mcmole/24 hours, 11 - ketoandrosterone up to 2.5 mcmole/24 hours, 11 - ketoetiocholanolone up to 2.5 mcmole/24 hours, 17 - ketosteroids up to 50 mcmole/24 hours and van de Calseyde's discriminant up to 3, the glucocorticoid Metypred is prescribed. The high blood concentration of luteinising hormone up to 15 mIU/ml, dihydroepiandrosterone sulphate up to 6.82 mcmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and an increase of urine androsterone up to 19.5 mcmole/24 hours, etiocholanolone up to 16 mcmole/24 hours, dihydroepiandrosterone up to 7 mcmole/24 hours, 17 - ketosteroids up to 45 mcmole/24 hours and van de Calseyde's discriminant up to 3.5 enables using the combined oral contraceptive Jess and the glucocorticoid Metypred. And the preparation Dostinex is prescribed in observing the above values in a combination with an increase of blood prolactin up to 750 IU/ml and a decrease of blood oestradiol up to 95.48 pcg/ml.EFFECT: method enables providing higher therapeutic selectivity and clinical effectiveness in acne without the need of thorough examination to be conducted.4 ex

Compositions, including at least one derivative of naphthoic acid, benzoylperoxide and at least one film-forming component, methods of their obtaining and application // 2526905
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of pharmaceutics, in particular represents composition for topic application, which includes, into physiologically acceptable medium at least one derivative of naphthoic acid, benzoylperoxide and at least one film-forming component.EFFECT: invention is characterised by the fact that said compound of naphthoic acid and benzoylperoxide are in dispersed in said composition form.23 cl, 14 ex

Topical herbal formulation for treating acne and skin disorders // 2526138
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to an herbal formulation of topical nanoemulsion for treating acne-related skin disorders. The above formulation contains an aqueous phase comprising a therapeutic agent, rose water and/or lemon juice, and an oil phase containing an essential oil, a non-ionic surfactant and an accessory surfactant. The aqueous and oil phases are related within the range of 1:1 to 1:2, while a particle size of the herbal formulation is less than 5 nm. The essential oil is presented by tea tree oil, basil oil, rosemary oil, lavender oil, jojoba oil, bergamot oil, clove oil and peppermint oil. The invention also refers to a method for preparing the herbal formulation which involves providing the aqueous and oil phases, mixing the above phases to produce a mixture to be emulsified with the non-ionic surfactant to prepare a macroemulsion. The prepared macroemulsion is mixed with ethanol to produce a nanoemulsion with a particle size less than 5 nm.EFFECT: invention provides the herbal formulation with good penetration, prolonged effect causing no irritation.8 cl, 4 dwg, 7 ex

Polyunsaturated fatty acid and diol ester as anti-acne medication // 2524779
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed invention relates to compounds of the following formula , in which n equals integer number from 1 to 15, m equals 0, 1, 2 or 3, and R represents hydrocarbon chain of polyunsaturated fatty acid, selected from omega-3 and omega-6 polyunsaturated fatty acids, and to method of obtaining them.EFFECT: development of pharmaceutical or cosmetic composition based on said compounds and to method of acne or seborrheic dermatitis treatment for cosmetic purposes.16 cl, 4 dwg, 2 tbl, 3 ex

3-substituted-1,4-diazepan-2-one antagonists of melanocortin 5-receptor // 2524245
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to a compound of formula (I)where Y represents a group of formula -(CR9R10)n-; X represents -C(=O)-; Z represents a group of formula -(CR13R14)q-; R1 is selected from a group, consisting of (a) C2-C12alkenyl, substituted with 4-chlorophenyl; or (b) C6-C10aryl, optionally substituted with one or two halogen atoms; R2 and R3 represent H; R4 is selected from a group, consisting of H, C1-C12alkyl, optionally substituted with hydroxyl, methoxy or benzyloxy, C3-C12cycloalkyl, C6aryl, optionally substituted with an amino group or pyperidine, C-bound C1-C18heteroaryl, selected from pyridine and imidazole, C(=O)R15, C(=O)NR16R17 and ONR16C(=NR17)NR18R19; each R5a and R5b represents H, each R6, R7 and R8 is independently selected from a group, consisting of H, C1-C12alkyl and C6-C18aryl, each R9 and R10 represents H; each R13 and R14 represents H; R15 represents H, each R16, R17, R18, R19 and R20 is independently selected from a group, consisting of H, C1-C12alkyl, C3-C12cycloalkyl, C6aryl and pyridyl, or any two of R16, R17, taken together with atoms, to which they are bound, form a cyclic group, containing 5 carbon atoms, or n equals to 1; q represents an integer number, selected from a group, consisting of 1, 2, 3, 4 and 5; r equals to 1; or its pharmaceutically acceptable salt.EFFECT: invention relates to a pharmaceutical composition for treatment of MC5R-associated conditions, which contains a formula (I) compound and a pharmaceutically acceptable carrier, a diluent or a filling agent.23 cl, 6 tbl, 53 ex
Extract from aboveground parts of oat grown before ear formation // 2517346
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, in particular to a composition, possessing immunomodulating and anti-inflammatory properties. The dermatological composition, possessing immunomodulating and anti-inflammatory properties, as an active ingredient, contains an extract of the aboveground part/parts of oat, collected before ear formation. The cosmetic composition, possessing immunomodulating and anti-inflammatory properties. Application of the extract of the aboveground part/parts of oat, collected before ear formation, possessing immunomodulating and anti-inflammatory properties, as a medication.EFFECT: composition and extract possess expressed immunomodulating and anti-inflammatory properties.15 cl, 1 tbl, 3 ex

Composition and method of treating pathological skin conditions // 2501544
FIELD: medicine.SUBSTANCE: invention refers to cosmetic industry and represents a non-foaming cosmetic composition of an oil-in-water emulsion containing (i) retinol, (ii) at least one polar emollient specified in a group consisting of propylene glycol stearyl ester, propylene glycol isostearate and mixtures thereof (iii) at least one non-polar emollient specified in a group consisting of aromatic or linear esters, Gerbe ester, mineral oils, squalane, isohexadecane, squalene, liquid paraffin and mixtures thereof with the weight ratio of the above polar emollient and the above non-polar emollient is found within the range of approximately 95 to 5 to approximately 40 to 60.EFFECT: provided considerable reduction of retinoid-caused skin irritation and higher efficacy or retinoid.11 cl, 3 ex, 7 tbl, 3 dwg
ethod of treating acne // 2495675
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely a method of treating acne. The method of treating acne by prescribing line seed oil 10 ml 2 times a day, sodium selenite 90 mcg 1 time a day, tocopherol acetate 100 mg 2 times a day for 1 month.EFFECT: method of treating acne is effective and enables reducing the length of treatment.
Pharmaceutical formulations for local application containing low concentrations of benzoyl peroxide in suspension in water and water-miscible organic solvent // 2493847
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to cosmetology and dermatology, and represents a water-based formulation for local application for treating acne, containing water, a water-miscible organic solvent and benzoyl peroxide, wherein the organic solvent concentration is 1-4 times higher than the benzoyl peroxide concentration in the formulation; the water and organic solvent concentrations are related as at least 7:1, preferentially at least 10:1, more preferentially at least 20:1; the benzoyl peroxide concentration in the formulation makes less than 5.0 wt %, but at least 1.0 wt %.EFFECT: invention provides the clinical effectiveness with the reduced active agent concentration, as well as reduced irritant action.27 cl, 4 ex, 3 tbl

Using natural active substances in cosmetic or therapeutic compositions // 2491910
FIELD: medicine.SUBSTANCE: invention refers to cosmetology and represents a cosmetic composition containing: hydrolised yeast proteins as an active substance, and at least one acceptable carrier, differing by the fact that the above hydrolised yeast proteins are prepared by exogenic enzymatic hydrolysis and/or acid hydrolysis and/or alkaline hydrolysis of the yeast membranes.EFFECT: invention provides improved cosmetic activity, excellent time stability.17 cl, 6 ex, 3 tbl, 2 dwg

Therapeutic regimen for acne-related diseases // 2490035
FIELD: medicine.SUBSTANCE: invention refers to medicine, specifically to dermatology, and may be used for treating the patients suffering acne. That is ensured by local applications of a therapeutically effective amount of a fixed-dose combination containing adapalene and benzoyl peroxide. That is combined with oral administration of a therapeutically effective amount of an antibiotic for a particular period of time.EFFECT: method provides the effective treatment of these patients, manifested as a significant decrease of all types of acne involvements, prevents the further development of these involvements, including after the withdrawal of oral antibiotics and the development of resistance, due to the synergistic effect of the above local combination and oral antibiotic.11 cl, 11 tbl, 4 dwg, 2 ex
Stabilised topical composition possessing comedolytic and antibiotic action // 2481845
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine and cosmetics, more specifically to a topical pharmaceutical composition possessing comedolytic and antibiotic action, comprising an effective amount of the antibiotic clindamycin, salicylic acid and excipients. The pharmaceutical composition is presented in the form of a gel. The excipients are as follows: acrylate copolymer emulsion Salcare SC80, allantoin, antioxidant dihydroquercetin preservative Sharomix MCI, propylene glycol, cyclomethicone DC 345, tocopherol phosphate, UV filter Escalol 567, emulsifier DC 5329, trometamol and thermal water.EFFECT: stabilised composition has strong comedolytic and antibiotic action, comprises the protective SPF factor which protects inflamed skin against the negative effects of UV radiation and has a shelf life of at least 3 years.3 ex, 4 tbl

Application of adapalene and benzoyl peroxide for long-term treatment of acne vulgaris // 2481832
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of pharmaceutics and represents application of composition, including adapalene and benzoyl peroxide, in preparation of local medication, intended for application by patient who requires it to provide long-term treatment of acne vulgaris, where scheme of application of local medication includes application of therapeutically efficient quantity of composition for, at least, 9 months.EFFECT: invention ensures achievement of stable positive effect in long-term treatment of acne with composition, including adapalene and benzoyl peroxide, as well as absence of side effects.19 cl, 1 ex, 3 dwg

1-aminoalkylcyclohexane derivatives for treatment of inflammatory skin diseases // 2481828
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of dermatology and represents application of 1-aminoalkylcyclohexane derivative, selected from neramexane and its pharmaceutically acceptable salts for treatment or prevention of inflammatory skin diseases, which represent acne, irritant dermatitis, impetigo and atopic dermatitis.EFFECT: invention ensures extension of arsenal of medications for treatment of inflammatory skin diseases.39 cl, 7 ex, 35 tbl, 5 dwg

ethod of treating patients suffering pustular skin disorders // 2479308
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly to dermatology, more specifically to methods of treating pyoinflammatory skin diseases, particularly furunculosis and acne. The method of treating the patients suffering pustular skin disorders, according to the invention, consists in the fact that the affected and surrounding skin areas are prepared with warm weak antiseptic, dried and further processed with an ointment prepared by thorough mixing on a water bath until smooth: zinc-salicylic paste, Lorinden C, gioxizone, streptocide liniment, synthomycin liniment and retinol acetate in the ratio of 3÷1÷1÷1÷0.8÷0.1 with skin treatment produced 2 times a day. The weak antiseptic is sodium bicarbonate or chamomile infusion at temperature 40-45°C. Besides, water bath temperature is to be 40-50°C, and the ointment is to be prepared is a glass or ceramic container. Face acne requires the affected area to be warmed with a vapour bath before finally applying the ointment. To prevent accidental wipe-out of ointment from the ointment treated skin, it is covered with the napkins attached to healthy skin. To enhance the effect of the ointment applications, the affected skin is exposed to UV lamp and/or sunlight for 10-30 minutes.EFFECT: method enables faster treatment and prevented the recurrent disease, and also ensures the prevention of side effects and provides outpatient treatment.6 cl, 7 dwg

Compositions containing benzoyl peroxide, at least one naphthoic acid derivative and at least one compound of polyurethane polymer or its derivative, methods for producing and applying them // 2459612
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to cosmetology and dermatology and represents a composition for treating dermatological disorders containing in a physiologically acceptable medium, at least: (i) peroxide benzoyl, (ii) a naphthoic acid derivative specified in 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 6- [3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthoic acid, 6-[3-(1-adamantyl)-4-decyloxyphenyl]-2-naphthoic acid and 6-[3-(1-adamantyl)-4-hexyloxyphenyl]-2-naphthoic acid and (iii) a compound of polyurethane polymer representing a polyol pre-polymer with said naphthoic acid derivative and said benzoyl peroxide being found in the dispersed form in said composition.EFFECT: invention provides producing a non-irritant stable composition.25 cl, 8 ex
Therapeutic composition for treating dermatopathies (versions) // 2456976
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry, and concerns preparing an agent for treating various dermatopathies: psoriasis, eczema, atopic dermatitis, ulcers incl. trophic and other diseases accompanied by inflammation or skin flaking. According to the first version, the composition contains ethoxylated alcohol, glycerol monostearate, higher fatty alcohols C16-C18 and cocoglycerides, as well as glycerol, olive oil and water. According to the other versions, it contains naphthalan oil or pentoxifylline or urea. All the versions provide a liposomal form of the composition improving healing, soothing and trophic effects.EFFECT: composition is hypoallergic, easy-to-use.12 cl, 8 ex

Benzimidazole derivatives, based pharmaceutical composition and methods of using them // 2456276
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.EFFECT: there are produced new benzimidazole derivatives showing PPARγ modulatory activity.41 cl, 2 dwg, 6 tbl, 76 ex
ethod of treating acne // 2455009
FIELD: medicine.SUBSTANCE: invention refers to medicine, specifically dermatology, and may be used for treating the acne. A standard drug-induced therapy is prescribed. From the first day of treatment, it is added with 10 sessions of subcutaneous puncture of morphological acne elements with an ozone-oxygen mixture with the ozone concentration of 3500 mcg/ml. The sessions are performed every second day. The volume of the injected ozone-oxygen mixture per each puncture makes 0.2 ml to 0,6 ml. Besides, the preparation Imunorix 800 mg is prescribed in the morning and in the evening orally between meals for the first 14 days of the therapy. Then, for the following 14 days, Imunorix is dosed 400 mg according to the previous regimen.EFFECT: method allows 29% higher clinical effectiveness in severe and moderate acne, including in patients with accompanying cardiovascular pathologies and with aggravated inflammatory diseases, due to lower intensity of inflammation processes and normalised immune status.2 ex
Dermatological agent 'belemnit' for acne and psoriasis // 2453305
FIELD: medicine.SUBSTANCE: invention refers to cosmetology and represents a dermatological agent for acne and psoriasis, containing Vaseline and mineral powder Belemnit, characterised by the fact that it additionally contains polyethylene glycol 200 and salicylic acid with the ingredients in the agent taken in certain proportions, wt %.EFFECT: invention provides eliminated cosmetic defects caused by clinical manifestations of psoriasis and acne.3 ex

Pharmaceutical compositions containing vitamin d and corticosteroid // 2452488
FIELD: medicine, pharmaceutics.SUBSTANCE: there are presented a pharmaceutical composition containing calcipotriene - at least one compound of vitamin D, at least one compound of corticosteroids (betamethasone dipropionate), paraffin, mineral oil, tocopherol and a solvent specified in a list: triglyceride, sorbitan, fatty sorbitan ester, cetearyl glucoside, polyethylene glycol-p-sorbitan stearate, an acrylamide and sodium acryloyldimethyltaurate copolymer, and their mixture, a method for making and applying it for preparing a drug for treating psoriasis. What is shown is the fact that: paraffin provides resistance to anhydrous calcipotriene in the composition with the corticosteroid betamethasone dipropionate.EFFECT: composition of calcipotriene and betamethasone dipropionate increases the compliance of the patient suffering psoriasis.13 cl, 3 tbl, 2 ex
Using actinomycetes lysate for preparing dermatics for treating acne and method of treating acne // 2445968
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to dermatology and represents using lysate of strains Actinomyces R/3.88, L/1.89 or their mixtures for preparing dermatics for treating acne, as well as a method for treating acne characterised by the fact that actinomycetes lysate according to cl.1 is applied on skin of a patient in need thereof.EFFECT: invention provides higher bioavailability of actinomycetes lysate, effective local concentration of the drug in focus of disease, reduced side effects.2 cl, 5 ex, 2 tbl
Dermatological application of milk proteins // 2445105
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to cosmetology and represents application of a protein fraction of milk whey containing 50 to 98 wt % of lactoferrin for making an oral composition for treating acne which is applied without adjunctive local treatment and wherein the protein fraction of milk whey is introduced in dose 40 to 800 mg per a patient a day.EFFECT: invention provides higher clinical effectiveness in acne.7 cl, 4 ex, 2 tbl
ethod of treating moderate acne // 2425682
FIELD: medicine.SUBSTANCE: treatment is carried out by administration of azythromycin according to the schedule. Azythromycin is taken 3 times a week for 6 weeks. For the first 3 weeks, azythromycin is taken in a dose 500 mg, and for the following three weeks - in a dose 250 mg.EFFECT: method is sparing for the patients suffering acne, provides reduced length of treatment and a course dose that has allowed to provide essentially higher clinical effectiveness with reduced risk of side effects.2 ex, 1 tbl

Compositions containing at least one naphthoic acid derivative and at least one compound of polyurethane polymer or its derivative, methods of producing and applying thereof // 2421216
FIELD: medicine, pharmaceutics.SUBSTANCE: composition for treating acne by topical application contains in a physiologically acceptable medium at least one naphthoic acid derivative and at least one compound of polyurethane polymer or its derivative, and the composition does not contain any saw palmetto fruit extract. Said naphthoic acid derivative is presented in the dispersed form in said composition.EFFECT: invention allows treating acne by a stable composition which does not cause irritation.26 cl, 8 dwg, 31 ex

Adapalene for long-term treatment of common acne // 2419424
FIELD: medicine.SUBSTANCE: claimed is application of adapalene in obtaining medication for local application for administering to patients in order to support their biological response in treatment of common acne, where the scheme includes introduction of therapeutically effective amount of adapalene, at least, one time per two days for, at least, 6 months, where medication for local application contains from 0.25% to 0.5% of adapalene in weight; or introduction of therapeutically effective amount of adapalene, at least, one time per two days for, at least, 6 months (versions). Claimed application ensures efficient treatment of common acne in long-term treatment without evidence of systemic toxicity. Expected signs and symptoms of skin irritation - mainly mild or temperate and transient - are observed.EFFECT: elaboration of efficient medication for acne treatment.11 cl, 2 dwg, 17 tbl
 
2551343.
Up!